News

Pfizer faces growth challenges with patent losses and waning COVID sales. Selling an ATM Put option expiring Nov'25 could ...
Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...
Pfizer offers a substantial 6.7% dividend yield and has increased its dividend for 16 consecutive years. The stock trades at a forward P/E of just 8.7, close to historical lows. Despite policy ...
Undoubtedly the biggest story of the week was the scrapping of the $160 billion merger between Pfizer and Allergan ... says WHO The World Health Organisation (WHO) released a report into worldwide ...
Pfizer and Allergan have confirmed that they ... driven by the potential savings they are able to deliver to healthcare systems. The ISPE Singapore Affiliate Conference & Exhibition is one of ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pfizer (PFE – Research Report), Nanobiotix (NBTX – Research ...
We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other ...
Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors ...
What Happened? A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White House clarified the tariffs on imports from China would add ...
In recent developments, a class action lawsuit was filed against Cerevel Therapeutics, Bain Capital Investors, and Pfizer ...
Pfizer PFE has sold off its remaining stake in consumer health company Haleon HLN to institutional investors and Haleon itself for around $3.3 billion. Pfizer sold its 7.3% stake in Haleon ...
Myriad reasons underlie the negative sentiment toward the healthcare sector, but in some instances, this dour take isn't entirely warranted. Pharmaceutical titan Pfizer (NYSE: PFE) is a case in point.